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1. INTRODUCTION 
 
Oral delivery of drugs is one of the most preferable route of delivery due to the ease of 
administration, patient compliance and flexibility in formulation etc.
1
 Controlled drug 
delivery systems are the delivery systems which extends the drug release and makes the 
drug release sustained and at predetermined rate. Floating or Gastroretentive drug 
delivery systems holds the advantage of both oral delivery and controlled delivery. 
Floating systems significantly extend the period of time, over which drug may be 
released and prolongs dosing intervals and increase patient compliance. These systems 
retain in stomach and improves the absorption window and thus enhances the 
bioavailability.
2
 
Floating dosage forms are oral dosage forms of tablets, capsules, or micro beads 
and contain hydrocolloids that allow floating by swelling thereby prolong the residence 
time of dosage form within G.I tract.
3
 
             Various gastroretentive techniques were used to achieve floating concept which 
includes floating, swelling, high density, and bioadhesive system, have been explored 
to increase the gastroretention of dosage forms.
4
 
Gastric emptying of dosage forms is an extremely variable process and ability to 
prolong and control the emptying time is a valuable asset for dosage forms, which 
reside in the stomach for a longer period of time than conventional dosage forms. 
Several difficulties are faced in designing controlled release systems for better 
absorption and enhanced bioavailability.
5
  
Gastro retentive systems can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric 
2 
 
retention improves bioavailability, reduces drug waste, and improves solubility for 
drugs that are less soluble in a high pH environment. It has applications also for local 
drug delivery to the stomach and proximal small intestines.  
 
FACTORS EFFECTING GASTRIC RETENTION
6,7,8 
 
 Density: GRT is a function of dosage form buoyancy that is  dependent 
on  the density.  
 Size: Dosage form units with a diameter of more than 7.5mm are reported 
to have an increased GRT compared with those with a diameter of 9.9mm.  
 Shape of dosage form:  Tetrahedron and ring shaped devices with  a 
flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI) are 
reported to have better GRT 90% to 100% retention at 24 hours compared 
with other shapes.  
 Single or multiple unit formulation: Multiple unit formulations show a 
more Predictable release profile and insignificant impairing of performance 
due to failure of units, allow co- administration of units with different 
release profiles or containing incompatible substances and permit a larger 
margin of safety against dosage form failure compared  with single unit 
dosage forms.  
 Fed or unfed state: Under fasting conditions, GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex 
(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach. However, in the fed state, MMC is delayed and 
GRT is considerably longer. 
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 Nature of meal: Feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release.  
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is 
high in proteins and fats.  
 Frequency of feed: The GRT can increase by over 400 minutes, when 
successive meals are given compared with a single meal due to the low 
frequency of MMC
.
  
 Gender:  Mean ambulatory GRT in males (3.4±0.6 hours) is less compared 
with their age  and race matched female counterparts (4.6±1.2 hours), 
regardless of the weight,  height and  body surface.  
 Age:  Elderly people, especially those over 70, have a significantly longer 
GRT.  
 Posture: GRT can vary between supine and upright ambulatory states of 
the patient.  
 Concomitant drug administration:  Anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like 
metoclopramide and cisapride.  
 Biological factors: Diabetes and Crohn’s disease.  
 
IDEAL DRUG CANDIDATES FOR FDDS
9,10
 
Drugs which are suitable for floating drug delivery systems are 
 Narrow absorption window in GI tract 
e.g., riboflavin and levodopa 
 Primarily absorbed from stomach and upper part of GI tract  
e.g., calcium supplements, chlordiazepoxide and cinnarazine 
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 Drugs that act locally in the stomach 
e.g., antacids and misoprostol 
 Drugs that degrade in the colon 
e.g., ranitidine HCl and metronidazole 
 Drugs that disturb normal colonic bacteria 
e.g., amoxicillin trihydrate  
 
TYPES OF FLOATING DRUG DELIVERY SYSTEMS   
Floating drug delivery systems have a bulk density less than gastric fluids and so 
remain buoyant in the stomach with out affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents the drug 
is released slowly at the desired rate from the system. 
Based on the mechanism of buoyancy FDDS may be classified as
11,12
 
 Effervescent System 
 Non- Effervescent System 
 
EFFERVESCENT SYSTEMS 
Effervescent systems reduces the density of the drug delivry system and float on the 
gastric fluid. It uses gas generating agents, carbonates (ex. Sodium bicarbonate) and 
other organic acid (e.g. citric acid and tartaric acid) present in the formulation to 
produce carbon dioxide (CO2) gas, thus reducing the density of the system and making 
it float on the gastric fluid. An alternative is the incorporation of matrix containing 
portion of liquid, which produce gas that evaporates at body temperature.  
 
Volatile liquid containing systems
13,14
 
The gastric residence time of a delivery system can be increased by incorporating an 
inflatable chamber, which contains a volatile liquid. e.g. ether, cyclopentane, that 
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gasifies at body temperature to cause the inflation of the chamber in the stomach. 
The device may also consist of a bioerodible plug made up of PVA, Polyethylene, 
etc.  
Gas generating Systems
15,16
 
These buoyant delivery systems utilize liberation of carbon dioxide from effervescent 
reaction between carbonate or bicarbonate salts and citric or tartaric acid. The 
liberated carbon dioxide gets entrapped in the hydrocolloid layer of the system. Thus 
the specific gravity decreases and the system begins to float. 
                                                      
NON-EFFERVESCENT SYSTEMS 
This type of system, after swallowing, swells apparently via imbibition of gastric fluid 
to an extent that it prevents their exit from the stomach. These systems may be referred 
to as the plug-type. The air trapped by the swollen polymer confers buoyancy to these 
dosage forms. 
 
Colloidal gel barrier systems
17,18
 
These systems contains drug with gel forming hydrocolloids meant to remain 
buoyant on stomach contents. These systems incorporate a high level of one or more 
gel forming highly swellable cellulose type hydrocolloids. On coming in contact with 
gastric fluid, the hydrocolloid in the system hydrates and forms a colloidal gel barrier 
around the gel surface. The air trapped by the swollen polymer maintains a density 
less than unity and confers buoyancy to this dosage forms. 
Microporous Compartment System
19,20
 
This technology is based on the encapsulation of drug reservoir inside a Microporous 
compartment with aperture along its top and bottom wall. The peripheral walls of the 
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drug reservoir compartment are completely sealed to prevent any direct contact of the 
gastric mucosal surface with the undissolved drug. In stomach the floatation chamber 
containing entrapped air causes the delivery system to float over the gastric contents. 
Gastric fluid enters through the apertures, dissolves the drug, and carries the dissolve 
drug for continuous transport across the intestine for absorption. 
 
Alginate beads
19,20
 
Multiple unit floating dosage forms have been developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm in diameter can be prepared by 
dropping a sodium alginate solution in to aqueous solutions of calcium chloride, 
causing precipitation of calcium alginate. The beads are then separated snap and 
frozen in liquid nitrogen, and freeze dried at -40°C for 24 hours, leading to the 
formation of porous system, which can maintain a floating fource over 12 hours.  
 
Hollow microspheres
19,20
 
Hollow microspheres (microballons), loaded with ibuprofen in their outer polymer 
shells were prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymers was poured in 
to an agitated aqueous solution of PVA that was thermally controlled at 40°C.The gas 
phase generated in dispersed polymer droplet by evaporation of dichloromethane 
formed in internal cavity in microspheres of the polymer with drug. The microballons 
floated continuously over the surface of acidic dissolution media containing 
surfactant for greater than 12 hours in vitro.  
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APPROACHES TO DESIGN OF FLOATING  DOSAGE  FORMS 
The following dosage forms have been used for the design of single and multiple unit 
dosage forms: 
Single unit dosage forms 
In this system the globular shells apparently having low density than that of gastric 
fluid can be used as a carrier for drug for its controlled release. Sugar polymeric 
materials such as methacrylic polymer and cellulose acetate phthalate have been used 
to undercoat these shells. These are further coated with a drug polymer mixture. The 
polymer of choice can be either ethylcellulose or hydroxypropyl cellulose depending 
upon the type of release desired. Finally, the product floats on the gastric fluid while 
releasing the drug gradually over a prolonged duration.
21
 
          It includes incorporation of gas filled floatation chamber into a microporous 
component that houses a drug reservoir. Apertures or openings are present along the 
top and bottom walls through which the gastrointestinal tract fluid enters to dissolve the 
drug. The other two walls in contact with the fluid are sealed so that the undissolved 
drug remains therein. The fluid present can be air, under partial vacuum or any other 
suitable gas, liquid or solid having an appropriate specific gravity and an inert behavior. 
The device is of swallowable size, remains afloat within the stomach for a prolonged 
time and after the complete release the shell disintegrates passes off to the intestine and 
is eliminated.
22
 
Single-unit formulations are associated with problems such as sticking together 
or being obstructed in the gastrointestinal tract, which may have a potential danger of 
producing irritation. Unfortunately floating devices administered in single unit 
form(HBS) are unreliable in prolonging the GRT owing to their ‘all or nothing’ 
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emptying process and thus they may cause high variability in bioavailability and local 
irritation due to large amount of drug delivered at a particular site of gastrointestinal 
tract.
23
 
Multiple -unit dosage forms 
Single unit dosage forms have lot of disadvantages, hence it is needed to develop a 
multiple unit dosage forms. Microspheres have high drug loading capacity and many 
polymers have been used such as albumin, gelatin, starch, PLGA, polymethacrylate, 
polyacrylamine and polyalkylcyanoacrylate. spherical polymeric microsponges, also 
referred to as microballoons,’’ have been prepared.24 Microspheres have a characterstic  
internal hollow structure and show invitro flotabilty. In carbon dioxide generating 
multiple-unit oral formulations several devices with features that extend, unfold or  are 
inflated by carbon dioxide generated in the devices after administration have been  
described in the recent patient literature. These dosage forms are excluded from the 
passage of the pyloric sphincter if a diameter of ~12 to 18mm in their expanded state is 
exceeded.
25,26
 
Advantages of FDDS
27,28
 
Floating dosage systems form important technological drug delivery systems with 
gastric retentive behavior and offer several advantages in drug delivery. These 
advantages include 
 Improved drug absorption, because of increased GRT and more time spent by 
the dosage form at its absorption site. 
 Controlled delivery of drugs. 
 Delivery of drugs for local action in the stomach. 
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 Minimizing the mucosal irritation due to drugs, by drug releasing slowly at   
controlled rate. 
 Treatment of gastrointestinal disorders such as gastro-esophageal reflux. 
 Simple and conventional equipment for manufacture. 
 Ease of administration and better patient compliance. 
 
Limitations
29,30
 
 The major disadvantage of floating system is requirement of a sufficient high 
level of fluids in the stomach for the drug delivery to float. However this 
limitation can be overcome by coating the dosage form with the help of 
bioadhesive polymers that easily adhere to the mucosal lining of the stomach. 
 Floating system is not feasible for those drugs that have solubility or stability 
problem in gastric fluids. 
 The dosage form should be administered with a minimum of glass full of water 
(200-250 ml). 
 The drugs, which are absorbed throughout gastro-intestinal tract, which under 
go firstpass metabolism (nifedipine, propanolol etc.) are not desirable candidate. 
 Some drugs present in the floating system causes irritation to gastric mucosa. 
 
EVALUATION OF GASTRO RETENTIVE DOSAGE FORMS 
Evaluation for gastro retention is carried out by means of X-ray or gamma scintigraphic 
monitoring of the dosage form transit in the GI tract.
31
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FORMULATION OF FLOATING DRUG DELIVERY SYSTEMS: 
Following types of the ingredients can be incorporated in to HBS dosage form 
 Hydrocolloids 
 Inert fatty materials 
 Release rate accelerants 
 Release rate retardants 
 Buoyancy increasing agents 
 Miscellaneous 
 
Hydrocolloids
32
 
Hydrocolloids are synthetics, anionic or non ionic like hydrophilic gums, modified 
cellulose derivatives. E.g. Acacia, pectin, agar, alginates, gelatin, casein, bentonite, 
veegum, MC, HPC, HEC, and Na CMC can be used. The hydrocolloids must hydrate 
in acidic medium i.e. gastric fluid is having pH 1.2. 
Acacia, pectin, gelatin, alginate, caesin etc., are generally used hydrocolloids. 
These should hydrate in acidic medium i.e., in gastric fluid at a pH of 1.2. 
 
Inert fatty materials 
33
 
Edible, pharmaceutical inert fatty material, having a specific gravity less than one can 
be added to the formulation to decrease the hydrophilic property of formulation and 
hence increases the buoyancy. Eg: Purified grades of beeswax, fatty acids, long chain 
alcohols, glycerides
,
 and mineral oils can be used.  
Edible, pharmaceutical inert fatty materials, having a specific gravity less than 1 can be 
added to formulation to decrease  the hydrophilic property of formulation  and hence 
increase the buoyancy. Examples: fatty acids, glycerides 
11 
 
Release rate accelerates
34
 
The release rate of the medicament from the formulation can be modified by including 
excipient like lactose and/or mannitol. These may be present from about 5-60% by 
weight. The release rate of medicaments from the formulation can be modified by 
including excipients like lactose or mannitol. 
 
Release rate retardant
35
 
Insoluble substances such as calcium phosphate, talc, magnesium stearate decreases 
the solubility and hence retard the release of medicaments. 
Insoluble substance such as talc, magnesium sterate decrease the solubility and hence 
retard the release of medicaments. 
 
Buoyancy increasing agents
36
 
Materials like ethyl cellulose can be used for enhancing the buoyancy of the 
formulation. Materials like ethyl cellulose, which has bulk density less than one, can 
be used for enhancing the buoyancy of the formulation. It may be adapted up to 80 % 
by weight. 
 
Adjuvants
36
 
Pharmaceutically acceptable adjuvants like preservatives, stabilizers, lubricants can be 
incorporated as per requirements. 
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ANATOMY OF  GASTROINTESTINAL TRACT 
The gastrointestinal tract consist of stomach, small intestine, pancreas and large 
intestine. 
Stomach 
The stomach is a 'j'-shaped organ, with two openings- oesophageal and the duodenal- 
and four regions- the cardia, fundus, body and pylorus. Each region performs different 
functions; the fundus collects digestive gases, the body secretes pepsinogen and 
hydrochloric acid, and the pylorus is responsible for mucus, gastrin and pepsinogen 
secretion.
37,38
 
Small Intestine 
The small intestine is the site where most of the chemical and mechanical digestion is 
carried out, and where virtually all of the absorption of useful materials is carried out. 
The whole of the small intestine is lined with an absorptive mucosal type, with certain 
modifications for each section. The intestine also has a smooth muscle wall with two 
layers of muscle; rhythmical contractions force products of digestion through the 
intestine (peristalisis). There are three main sections to the small intestine; 
The duodenum forms a 'C' shape around the head of the pancreas. Its main function is 
to neutralise the acidic gastric contents (called 'chyme') and to initiate further digestion; 
Brunner's glands in the submucosa secrete an alkaline mucus which neutralises the 
chyme and protects the surface of the duodenum.
39
 
The jejunum  and The ileum. The jejunum and the ileum are the greatly coiled parts of 
the small intestine, and together are about 4-6 metres long; the junction between the 
two sections is not well-defined. The mucosa of these sections is highly folded (the 
13 
 
folds are called plicae), increasing the surface area available for absorption 
dramatically.
40
 
Pancreas 
The pancreas consists mainly exocrine glands that secrete enzymes to aid in the 
digestion of food in the small intestine. The main enzymes produced are lipases, 
peptidases and amylases for fats, proteins and carbohydrates respectively. Pancreatic 
exocrine secretion is hormonally regulated, and the same hormone that encourages 
secretion (cholecystokinin) also encourages discharge of the gall bladder's store bile.
 41
  
Large Intestine 
The large intestine is the second to last part of the digestive system—the final stage of 
the alimentary canal is the anus —in vertebrate animals. Its function is to absorb water 
from the remaining indigestible food matter, and then to pass useless waste material 
from the body.
 42
 
The large intestine consists of the cecum and colon. It starts in the right iliac region of 
the pelvis, just at or below the right waist, where it is joined to the bottom end of the 
small intestine. From here it continues up the abdomen, then across the width of the 
abdominal cavity, and then it turns down, continuing to its endpoint at the anus The 
large intestine is about 1.5 metres (4.9 ft) long, which is about one-fifth of the whole 
length of the intestinal canal.
 43
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Fig 1 Anatomy of Gastrointestinal tract 
PHYSIOLOGY OF GASTROINTESTINAL TRACT 
  
 Anatomically the stomach is divided into 3 regions:
 44,45,46
  
 Fundus 
 Body and  
 Antrum (pylorus). 
15 
 
            The proximal part made of fundus and body acts as a reservoir for undigested 
material, whereas the antrum is the main site for mixing motions and act as a pump for 
gastric emptying by propelling actions. 
           Gastric emptying occurs during fasting as well as fed states. The pattern of 
motility is however distinct in the 2 states. During the fasting state an interdigestive 
series of electrical events take place, which cycle both through stomach and intestine 
every 2 to 3 hours. This is called the interdigestive myoelectric cycle or migrating 
myoelectric cycle (MMC), which is3.Phase III (burst phase) lasts for 4 to 6 minutes. It 
includes intense and regular contractions for short period. It is due to this wave that all 
the undigested material is swept out of the stomach down to the small intestine. It is 
also known as the housekeeper wave .further divided into following 4 phases, they are : 
1.Phase I    (basal phase) lasts from 40 to 60 minutes with rare contractions 
2.Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action potential 
and contractions. As the phase progresses the intensity and frequency also increases 
gradually. 
3.Phase III  (burst phase) lasts for 4 to 6 minutes. It includes intense and regular 
contractions for short period. It is due to this wave that all the undigested material. 
4.Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2 
consecutive cycles .s swept out of the stomach down to the small intestine.  
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                                      Fig2. Physiology Of Gastrointestinal Tract 
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2. AIM AND OBJECTIVES 
Almost all drugs have side effects, this is due to toxic nature of the drug entity. Further 
due to the travelling or mailing of drug to one place to another place in body may produce side 
effects in different organs unnecessarily. So it is necessary to achieve the drug to specific 
targeted site. Lot of approaches is available. But most of the approaches are having practical 
difficulties. One of the good and significant approaches is to deliver the drug as floating tablets, 
which is termed as floating drug delivery systems. 
 The present research focused on the delivery of candesartan cilexetil via floating drug 
delivery system. This remains in the site of application i.e. in GIT. By this the degradation of 
drug is minimized. Further it may produce good therapeutic concentration in the system. 
  Floating drug delivery systems can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention 
improves bioavailability, reduces drug waste, and improves solubility for drugs that are less 
soluble in a high pH environment. 
Hypertension is a chronic disease condition in which the systemic arterial blood 
pressure is elevated. Anti-hypertensive drugs are used in the treatment of several cardiovascular 
disorders, particularly angina pectoris, supraventricular tachycardia and hypertension. 
            Candesartan Cilexetil, an antihypertensive drug competes with angiotensin II for 
binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also 
stimulates the synthesis and release of aldosterone, blockage of its effects results in a decrease 
in systemic vascular resistance. 
 The present work was aimed to prepare floating tablets of Candesartan Cilexetil with 
increased bioavailability and controlled release property. 
 
18 
 
The overall aim and objective of the present work was to 
 Formulate candesartan cilexetil floating tablets (CF1-CF6)  
 Evaluation of formulated candesartan cilexetil floating tablets (CF1-CF6)  
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3. LITERATURE REVIEW 
 Somani VG et al., (2009)
47  
developed  hollow calcium pectinate beads for floating 
pulsatile release of aceclofenac intended  for chronopharmacotherapy.  Floating pulsatile 
concept was applied to increase the gastric residence of the dosage form having lag 
phase followed by a burst release. The method used for the development of the beads 
was a simple process of acid-base reaction during ionotropic cross linking. The floating 
beads obtained were porous, hollow with a bulk density < 1 and had Ft50of 14-24 h. The 
floating beads showed a two-phase release pattern with initial lag phase during floating 
in an acidic medium followed by rapid pulse in phosphate buffer. 
 
 Jain AK et al., (2009)
48
 prepared and evaluated buoyant microspheres using famotidine 
as a model drug. The microspheres were prepared by solvent evaporation method using 
different polymers i.e., acrylcoat S 100 and cellulose acetate. The size or average 
diameter characterized by optical microscopy method and surface morphology was 
recognized by SEM. 
 
 
 Nath B et al., (2009)
49
 designed a sustained release floating microcapsules of 
Metformin HCl using cellulose acetate butyrate and Eudragit RL100 by oil-in-oil 
emulsion solvent evaporation method. Polymers were used separately and in 
combination (1:1) to prepare different microcapsules using acetone as organic phase. 
FT-IR study showed no drug polymer interaction. All the prepared microcapsules 
showed higher amount of drug release in phosphate buffer (pH 6.8) as compared to the 
release in 0.1M HCl (pH 1.2).  
 
 Nekkanti et al., (2009)
 50
 developed solid oral dosage form incorporating candesartan 
nanoparticles by wet bead milling technique. The solid-state properties of candesartan 
20 
 
cilexetil before and after milling were evaluated by X-ray powder diffraction (XRPD) 
and differential scanning calorimetry (DSC) analysis. The milled nanosuspension was 
converted into solid intermediate using a spray drying process. The spray dried 
nanosuspensions were characterized for particle size distribution (PSD) after 
reconstitution to understand the impact of spray drying process on PSD. The spray 
dried nanoparticles were blended with excipients for tableting. XRPD and DSC 
analysis indicated no phase transitions. The spray dried nanoparticles showed complete 
recovery following redispersion in water. The rate and extent of drug dissolution in 
physiologically relevant dissolution medium for tablet formulation incorporating drug 
nanoparticles was significantly higher as compared to commercial tablet formulation. 
The results from dissolution studies indicated significant increase in the rate of drug 
dissolution in physiologically relevant dissolution medium. 
 
 Thamizarasi S et al., (2009)51 prepared and evaluated poly(ɛ-caprolactone) 
microspheres of repaglinide by using solvent evaporation technique with different drug 
to carrier ratio. The microspheres were characterized for practical size, SEM, FT-IR 
study, percentage yield, drug entrapment, stability studies and in vitro drug release. The 
shape of microspheres were found to be spherical by SEM. 
 
 
 Gattani YS et al., (2008)
52
 formulated and evaluated floating microparticulate oral 
drug delivery system of diltiazem hydrochloride. Floating microspheres were prepared 
by non-aqueous emulsification solvent evaporation technique using ethyl cellulose and 
eudragit RS-100 as the rate controlling polymer. The in vitro evaluation, drug-polymer 
compatibility,percent yield, particle size analysis, drug entrapment efficiency, in vitro 
floatability, surface topography and in vitro release were performed. 
 
21 
 
 Jimenez I et al., (2008)53 developed a sustained delivery of captopril from floating 
matrix tablets. The study was done using metolose SH4000/ sodium bicarbonate and at 
two different compaction pressures. The observation showed that the matrices 
compacted at lower pressure (55MPa) float in the dissolution medium for more than 8h 
while those compacted at 165MPa float only when sodium bicarbonate is included in 
the formulation. The matrix density is lower when compacted at lower pressure keep 
more entapped air, decreasing the agglomerate density and allowing the tablets float, 
on the other hand, tablets compacted at higher pressure  are less porous and display a 
density not allowing the matrices floatation. An increasing proportion of the swelling 
polymer in the matrix increases. The increasing proportion of the swelling polymer in 
the matrix increases the maximal hydration volume as well as the time necessary to 
attain it. The release profiles of captopril form metolose matrices display greater 
percentages of drug released compared to similar matrices containing sodium 
bicarbonate due to an obstruction effect of the diffusion path by carbon dioxide 
bubbles. 
 
 Liu Q et al., (2008)54 prepared a zero order delivery of a highly soluble, low dose drug 
Alfuzosin hydrochloride via gastro-retentive system which were prepared as two 
multilayer delivery systems. First formulation compressed a triple layer based on PEO 
while the second formulation was a bilayer composite matrix system composed of 
hydroxylpropylcellulose and hydroxypropylmethylcellulose. The observation showed 
that the systems demonstrated controlled release kinetics independent of pH changes 
with about 99% of dose being released around 18h. The maintenance of constant 
surface area during dissolution is critical for zero-order drug delivery. The burst release 
suppression effect brought about by raped initial swelling and controlled erosion of 
layers provided for programmed controlled delivery and enhanced floatation 
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 Kale RD et al., (2007)
55
 prepared floating drug delivery system of piroxicam 
microspheres using enteric polymer by emulsification technique. The microspheres 
remained buoyant continuously over the surface of acidic media containing surfactant 
for the period of 8-12 hrs in vitro. DSC and XRD studies showed that drug 
incorporated in the outer shell of polymer was completely amorphous. SEM indicated 
that the microsphere is perfect sphere with an internal hollow cavity enclosed by a rigid 
shell of polymer. 
 
 Raval JA  et al., (2007)
56
 prepared Ranitidine hydrochloride floating matrix tablets 
based on low density powder: effects of formulation and processing parameters on drug 
release. The absorbance of Ranitidine hydrochloride solutions was measured at 315 nm 
using a Shimadzu UV-1601 UV/Vis double beam spectrophotometer. 
 
 
 Gambhire MN et al (2007)
57
 developed floating drug delivery system of diltiazem 
hydrochloride using rate retardant polymers. Floating matrix tablet of diltiazem 
hydrochloride was prepared by direct compression method. The effect of tablet 
hardness on release profile was also studied. Sodium bicarbonate was used as gas 
generating agent. The study showed the effect of excipient on release profile of drug 
and use of   floating controlled drug delivery. 
 
 Ali. J et al., (2007)
 58
 developed a hydrodynamically balanced system of metformin as 
a single unit floating capsule. Various grades of low-density polymers were used for 
the formulation of this system. They were prepared by physical blending of Metformin 
and the polymers in varying ratios. The formulation was optimized on the basis of in 
vitro buoyancy and in vitro release in simulated fed state gastric fluid (citrate 
phosphate buffer pH 3.0). Effect of various release modifiers was studied to ensure the 
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delivery of drug from the HBS capsules over a prolonged period. Capsules prepared 
with HPMC K4M and ethyl cellulose gave the best in vitro percentage release and was 
taken as the optimized formulation. In vivo studies were carried out in rabbits to assess 
the buoyancy, as well as the pharmacokinetic parameters of the formulation using 
gamma scintigraphy.  
 
 
 Bardonn et al., (2006)
59
 The challenge to develop efficient gastroretentive dosage 
forms began about 20 years ago, following the discovery of Helicobacter pylori by 
Warren and Marshall. In order to understand the real difficulty of increasing the gastric 
residence time of a dosage form, we have first summarized the important physiologic 
parameters, which act upon the gastric residence time. Afterwards, we have reviewed 
the different drug delivery systems designed until now, i.e. high-density, intragastric 
floating, expandable, superporous hydrogel, mucoadhesive and magnetic systems. 
 
 Patil JM et al., (2006)60 investigated rate controlled drug delivery system to solve 
physiological problems, such as short gastric residence time (GRT) and unpredictable 
gastric emptying times. Prolonged GRT may widen the stomach potential as the drug 
absorbing organ. Several approaches are currently utilized in GRT, floating drug 
delivery system (FDDS), swelling and expanding systems, polymorphic bioadhesive 
systems, modified shape systems, high density systems and other delayed gastric 
emptying devices were discussed in detail.
 
 
 
 Arora S et al.,  (2005)61 investigated floating drug delivery systems (FDDS) to 
compile the recent literature with special focus on the principal mechanism of 
floatation to achieve gastric retention. The recent developments of FDDS including the 
physiological and formulation variables affecting gastric retention, approaches to 
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design single-unit and multiple-unit floating systems, and their classification and 
formulation aspects are covered in detail. This review also summarizes the in vitro 
techniques, in vivo studies to evaluate the performance and application of floating 
systems, and applications of these systems. These systems are useful to several 
problems encountered during the development of a pharmaceutical dosage form. 
 
 Wei et al., (2004)62 developed a pH dependent floating sustained release tablet for 
gastric retention of 5-FU and prepared two layer floating tablet wherein floating ability 
is independent of the gastric acidity variation. 
 
 
 Li et al., (2003)63 investigated the effect of formulation variables on the calcium 
release and floating properties of the delivery system by using 2x3 factorial designs by 
using different grades of Hydroxypropylmethylcellulose (K100LV and K4M) and 
carbopol. They reported that by increasing the HPMC viscosity the release rate 
decreases and floating properties improved as the viscosity of the polymer is increased. 
Carbopol (CP934) incorporation was found to compromise the floating capacity of 
floating and release of calcium. 
 
 Umamaheswari RB et al., (2002)64 prepared floating microspheres containing the 
antiurease drug acetohydroxamic acid (AHA) by a novel quasi-emulsion solvent 
diffusion method. The microballons were coated with 2% w/v solution of 
polycarbophil by the air suspension coating method. The bioadhesive property of the 
microspheres was investigated by the detachment force measurement method. In vitro 
growth inhibition studies were performed in isolated H. pylori culture. The results 
suggest that AHA-loaded floating microspheres are superior as potent urease inhibitors 
whereas urease plays an important role in the colonization of H. pylori. 
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 Joseph NJ et al., (2002)65 prepared floating type dosage form of piroxicam in hollow 
polycarbonate (PC) microspheres capable of floating on simulated gastric and intestinal 
fluids was prepared by a solvent evaporation technique. Incorporation efficiencies of 
over 95% were achieved for the encapsulation. In vitro release of piroxicam from PC 
microspheres into simulated gastric fluid at 37ºC showed no significant burst effect. 
The amount released increased with time for about 8 h after which very little was found 
to be released up to 24 h. In intestinal fluid, the release was faster and continuous and 
at high drug payloads, the cumulative release reached above 90% in about 8 h. 
 
 Zhang J et al., (2000)66 developed floating tablets of Captopril using HPMC K4M and 
K15M and Carbopol 934P. Study was concluded that buoyancy of tablet is governed 
by both the swelling of the hydrocolloid particles on the tablet surface when it contacts 
the gastric fluids and the presence of internal voids in the center of the tablet. 
 
 
 Iannuccelli et al., (2000)67 used PVP solid dispersions for the controlled release of 
furosemide from a floating multiple-unit system. Furosemide has “absorption window” 
in the upper gastrointestinal tract. So it was necessary to increase gastric residence time 
for furosemide. The complete dose release over the actual intra-gastric residence time 
of the system (about 8 hr) was achieved by loading both the core and the membrane 
forming the units with 1:5 furosemide: PVP solid dispersion. Physicochemical analysis 
suggested that amorphous state of furosemide enhanced drug solubility and dissolution 
rate, which led to the desired release profile from the floating units. 
 
 Ozdemir et al., (2000)68 developed floating bilayer tablet of furosemide- cyclodextrin 
inclusion complex. They determined the gastric residence time using radiographs by 
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adding BaSO4 and reported that the tablet stayed in stomach for 6 hours. Also the 
bioavailability of furosemide from floating tablet was about 1.8 times that of the 
conventional tablet and also significant in vitro – in vivo correlation was detected. 
 
 
 Krogel and Bodmeier (1999)69 developed and evaluated floating drug delivery system 
based on effervescent core and a polymeric coating. The mechanical properties 
(puncture strength and elongation) of acrylic (Eudragit RS, RL and NE) and cellulose 
(cellulose acetate, ethyl cellulose) polymer, which primarily determined the type of 
delivery system, a polymer coating with a high elongation value and high water low 
carbon dioxide permeability was selected (Eudragit RL/ acetyl tributyl citrate 20%w/w) 
in order to initiate the effervescent reaction and the floating process rapidly. HPMC 
was also added in the core to retard drug release. The composition and hardness of the 
tablet core and the composition and hardness of the coating could control the time of 
flotation. 
 
 Lee et al., (1999)70 prepared floating acrylic resin microspheres with an internal hollow 
structure by a solvent diffusion and evaporation method. The yield of microspheres 
depended on the diffusion rate of ethanol and/or isopropanol in the gastric phase. Best 
results were obtained at the volume ratio of Ethanol: Isopropanol: dichloromethane 
(8:2:5). When a drug had low solubility in dichloromethane, the loading efficiency was 
the lowest. 
 
 
 Chen and Hao (1998)71 studied the in vitro performance of floating sustained release 
capsule of verapamil. Capsules filled with mixture of verapamil, HPC and effervescent 
materials are proposed to provide floating and sustained release for over 10 hrs. The 
effects of weight filled in the capsule, amount of HPC and the addition of effervescent 
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material on the dissolution kinetics were studied. They concluded that the release of 
Verapamil from the capsule followed Higuchi release model. However, when 
effervescent material was added, the system showed a zero-order release. 
 
 Gerogiannis et al., (1993)72 examined the floating and swelling characteristics of 
several excipients used in controlled release technology. The floating behavior was 
evaluated with resultant weight measurements, while a gravimetric method was 
employed for studying their swelling. The results indicated that higher molecular 
weight polymers had slower rates of polymer hydration and usually followed by 
enhanced floating behavior. 
 
 
 Oth M  et al., (1992)73 developed bilayer floating dosage unit to achieve local delivery 
of Misoprostal. The system was capsule consisting of a floating layer maintaining the 
dosage unit buoyant upon the gastric content and drug layer formulated to act as a 
sustained delivery system. The differential design of the two layers allows the 
optimization of both floating capability and drug release profile.   
 
 Desai and Bolton (1993)74 developed controlled release floating tablets of the 
theophylline using agar and light mineral oil. Tablets were made by dispersing drug 
and mineral oil mixture in a warm agar solution. The resultant mixture was poured into 
tablets moulds, which on cooling and air-drying formed floatable CR tablets. The light 
mineral oil was essential for the floating property of the tablets since relatively high 
amount of the drug (75%) was used. 
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DRUG PROFILE 
CANDESARTAN CILEXETIL
75-80 
Name 
Candesartan cilexetil 
Colour 
 White to off white 
IUPAC Name 
            2-ethoxy-3-[[4-[2-(2H-tetrazol-5yl)phenyl]phenyl]methyl]benzimidazole-4-
carboxylic acid 
Molecular Formula 
 C24H20N6O3 
Chemical Structure 
 
Fig 3. Structure of candesartan cilexetil 
Molecular Weight  
610.659660 [g/mol] 
Melting Point 
163
0
C 
Solubility  
Sparingly soluble in methanol, insoluble in water 
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PHARMACOLOGY 
Mechanism of Action  
Candesartan competes with angiotensin II for binding at the AT1 receptor subtype. As 
angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of 
aldosterone, blockage of its effects results in a decrease in systemic vascular resistance. 
 
PHARMACOKINETICS  
Bioavailability  
15% 
Distribution 
 Vd is 0.13 L/kg 
Metabolism 
 Candesartan cilexetil is bioactivated by ester hydrolysis during absorption from 
the GI tract to candesartan. Candesartan undergoes minor hepatic metabolism by O-
deethylation to an inactive metabolite. 
Elimination 
 Primarily as unchanged drug in the urine and by the biliary route, in the feces. 
Plasma Cl is 0.37 mL/min/kg. Renal Cl is 0.19 mL/min/kg. 26% is excreted unchanged 
in urine. 
Half Life  
Approximately 9 hrs 
THERAPEUTIC USES 
Candesartan cilexetil is used to treat hypertension. 
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ADDITIVES PROFILE 
SODIUM BICARBONATE
81,82
 
Chemical Name 
           Carbonic acid monosodium salt 
Formula:  
  NaHCO3 
Physical and chemical properties 
Molecular weight                  :          84.01 
Colour                                  : White   
Nature                            : Crystalline powder 
Odour   : Odourless 
Taste   : Saline/slight alkaline 
Density   : 0.869-2.173 g/cm
3
 
Moisture content   : less than 1%w/w 
Solubility   : Soluble in water, practically insoluble in   
                                                           ethanol   (95%) and ether. 
Melting point  : 270 C (with decomposition) 
Functional category 
 Alkalizing agent, therapeutic agent 
Applications 
 Used in pharmaceutical formulation as a source of carbon dioxide in 
effervescent tablets and granules. 
 Used to produce or maintain an alkaline pH in a preparation, like solution of 
Erythromycin, Lidocaine, and Niacin etc. 
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 Used to produce a sodium salt of the active ingredient that has enhanced 
solubility. 
 Used as a freeze-drying stabilizer and in toothpaste. 
Stability and Storage 
  Sodium bicarbonate is stable in dry air but slowly decomposed in moist air 
and should therefore be store in well-closed container in a cool dry place. 
Safety 
           Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution of 
carbon dioxide and may cause stomach cramps and flatulence (Rowe et al., 2003). 
 
POLY VINYL PYROLIDONE K-30
81,82
     
Chemical Name  
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula  
(C6H9NO)n 
Molecular Weight  
50 000 
Structural Formula     
 
Fig 4. Structure of PVP K30 
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Functional Category  
Disintegrant; dissolution aid; suspending agent; tablet binder. 
Description 
It occurs as a fine, white to creamy-white coloured, odourless or almost 
odourless, hygroscopic powder. It is manufactured by spray-drying and occurs as 
spheres. 
Flowability 
 16 g/s. 
Melting point 
150°C. 
Moisture content 
Very hygroscopic, significant amounts of moisture being absorbed at low 
relative humidities. 
Applications  
It is primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet-granulation processes. Povidone is also added to powder blends in the 
dry form and granulated in situ by the addition of water, alcohol, or hydroalcoholic 
solutions. Povidone is used as a solubilizer in oral and parenteral formulations and has 
been shown to enhance dissolution of poorly soluble drugs from solid-dosage forms.  
 
ETHYL CELLULOSE
81,82
  
Synonyms  
 Aqualon, Ethocel, Surelease  
Chemical name  
 Cellulose ethyl ether  
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Application 
 Ethyl cellulose is widely used as coating agent, , tablet binder, tablet filler and 
viscosity-increasing agent. The main use of ethyl cellulose in oral formulations is as 
hydrophobic coating agent for tablets and granules. Ethyl cellulose coatings are used to 
modify the release of a drug, to mask an unpleasant taste or to improve the stability of 
formulations.  
Solubility 
 Ethyl cellulose is practically insoluble in glycerin, propylene glycol and water. 
It is soluble in chloroform, methyl acetate, dichloromethane and tetrahydrofuran. But 
soluble in mixtures of 20 parts of ethanol (96 %) and 80 parts of toluene (w/w).  
Description 
 Ethyl cellulose is tasteless, white to light tan-coloured powder, free-flowing  
pH 
The pH of a 2 % w/w aqueous suspension is 5-7.5.  
Viscosity 
A wide range of viscosity type of ethyl cellulose is available. The range of 
viscosities is nominally from 7 to 100 mPa s (7-100cP).  
Stability  
Ethyl cellulose is stable powder, it is slightly hygroscopic. .It is chemically 
résistance to alkalies, both dilute and concentrated. Ethyl cellulose is subject to 
oxidative degradation in the presence of sunlight or UV light at elevated temperatures 
should be stored at a temperature not exceeding 32 degrees in a dry area away from all 
sources of heat. 
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HYDROXYPROPYL METHYLCELLULOSE(HPMC)
 81,82
 
Synonyms 
  Methocel, Methylcellulose, cellulose, hydroxypropylmethyl ether, 
hypromellose 
Molecular weight 
  Ranges between 10000 to 1500000 
Description 
  Odourless, tasteless, creamy white powder 
 Solubility  
 Soluble in cold water, practically insoluble in Chloroform, ethanol (95%) 
and ether but Soluble in mixture of ethanol and Dichloromethane. 
Viscosity                                         
HPMC-K4M-3,000-5600mPas, K15M: 12,000-21,000mPas, K100M: 80,000-1, 
20,000mPas 
Melting point                               
Browns at 190-200 C. 
Functional Category  
Coating agent, film-forming, rate-controlling polymer for sustained release,                
stabilizing   agent, suspending agent, tablet binder, viscosity-increasing agent. 
Application 
 In oral product HPMC is primarily used as tablet binder, in film coating and as 
an extended release tablet matrix. Concentration between 2-5% w/w may be 
used as a binder in either wet or dry granulation process. High viscosity grade 
may be used to retard the release of water-soluble drug from a matrix. 
 HPMC is widely used in oral and topical pharmaceutical formulation. 
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 Concentration of 0.45-1% w/w may be added as a thickening agent to vehicle 
for eye drop and artificial tear solution. 
 HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard 
contact lenses. It is widely used in cosmetics and food products. 
 In addition, HPMC is used as an emulsifier, suspending agent and stabilizing 
agent in topical gels and ointments. As a protective colloid, it can prevent 
droplets and particle from coalescing or agglomerating thus, inhibiting the 
formation of sediments. 
Stability and storage 
 It is stable although it is slightly hygroscopic. The bulk material should be 
stored in an airtight container in a cool and dry place. Increased in temperature reduces 
the viscosity of the solution.  
 
CARBOPOL 934
81,82
 
Synonyms  
Acritamer; acrylic acid polymer; Carbopol; carboxy polymethylene, polyacrylic acid; 
carboxyvinyl polymer; Pemulen; Ultrez.  
Chemical Name 
 Carbomer  
Molecular Weight   
 3x10
6
D 
Functional Category 
 Bio adhesive, emulsifying  agent, suspending  agent, tablet binder, viscosity 
increasing agent, release modifying agent.  
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Applications  
Carbopol 934 is used mainly in liquid or semisolid pharmaceutical formulations 
as suspending or viscosity increasing agent. Formulation including Creams, gels and 
ointments for in ophthalmic rectal and topical preparations. In the tablet formulations 
carbomers are used as dry or wet binder and as a rate controlling excipients.  
Carbomer rasines have also been investigated in the preparation of sustained release 
matrix beads, as enzyme inhibitors of intestinal proteases in peptide containing dosage 
forms, as a bioadhesive patch for cervical patch and for intranasally administered 
microspears, in magnetic granules for site specific drug delivery to the esophagus and 
in oral mucoadhesive controlled drug delivery system 
Stability 
Carbopol is stable and should be stored in tight containers.  
Incompatibilities 
Carbomer are discolored by resorcinol and are incompatible with phenol, cationic 
polymers strong acids and high level of electrolyte  
 
XANTHAM GUM
81,82
  
Synonyms  
Corn sugar gum; E415; Xantural; Rhodigel 
Chemical name  
 Xanthan gum.  
Molecular Weight  
 2000000  
Description  
 Cream or white-colored odorless free flowing fine powder.  
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Solubility  
 Practically insoluble in ethanol and ether. Soluble in cold or warm  
water.  
Viscosity  
The viscosity of xantham gum solution is considerably increased or gelation 
occurs, in the presence of some materials such as ceratonia, guar gum and magnesium 
aluminium silicate.  
Incompatibilities   
Xantham gum is an anionic material and is not usually compatible with cationic 
surfactants as precipitation occurs. Xantham gum is compatible with most synthetic and 
natural viscosity increasing agents.  
Functional Category   
Viscosity increasing agent, suspending agent.  
Applications   
Xantham gum is widely used in oral and topical pharmaceutical formulations. It 
is used as Viscosity increasing agent, suspending agent, and also has been used to 
prepare sustained release matrix tablets.  
Stability  
It is a stable material. The bulk material should be stored in a well closed 
container in a cool, dry place. 
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MAGNESIUM STEARATE
81,82
  
Synonyms 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt.  
Chemical Name  
 Octadecanoic acid magnesium salt  
Empirical formula  
 C36H70MgO4  
Molecular Weight  
591.34  
Structural formula  
 [CH3(CH2)16COO]2Mg  
Category  
 Tablet and capsule lubricant.  
Description  
A very fine, light white, precipitated or milled, impalpable powder of low bulk 
density, having a faint odor of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin.  
Solubility  
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble 
in warm benzene and warm ethanol (95%).  
Applications  
Widely used in cosmetics, foods, and pharmaceutical formulations. As a 
lubricant in capsule and tablet manufacture at concentrations between 0.25% and 5.0% 
w/w. Also used in barrier creams. 
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TALC
81,82
 
Synonyms  
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore  
Chemical Name  
Talc  
Empirical formula  
Mg6 (Si2O5)4(OH) 4  
Category  
Glidant; tablet and capsule diluent; tablet and capsule lubricant.  
Description 
Very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to the touch and free from grittiness.  
Solubility  
 Insoluble in dilute acids and alkalis, organic solvents, and water.  
Incompatibilities  
Incompatible with quaternary ammonium compounds.  
Applications 
Used as a dissolution retardant in the development of controlled-release 
products, as a lubricant in tablet formulations; in a novel powder coating for extended-
release pellets, and as an adsorbant. 
 
 
40 
 
4. PLAN OF WORK 
 
PREFORMULATION STUDIES 
 Drug – Additives Compatibility Study 
 Fourier Transform Infra-Red (FTIR) Study 
 Evaluation of flow properties of Powder Blends:- 
     Angle of Repose  
 Bulk Density  
 Tapped Density  
 Compressibility Index 
 Hausner’s  Ratio  
 
FORMULATION STUDIES 
          Formulation of candesartan cilexetil floating tablets (CF1- CF6) 
 
EVALUATION STUDIES 
 Weight variation  
 Thickness 
 Hardness 
 Friability 
 Assay 
 Floating lag time 
 Floating time 
 In vitro release 
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5. MATERIALS AND METHODS 
Table 1 List of Materials 
S.No. MATERIAL SOURCE 
1 Candesartan  cilexetil Aurobindo pharma Pvt Ltd, Hyderabad 
2 Carbopol934 Biochemika reagents 
3 HPMC Otto reagents 
4 Xanthum gum SD Fine Chemicals Ltd 
5 Tartaric acid Spectrum reagents, cochin 
6 Sodium bicarbonate Sisco research laboratories pvt ltd, Mumbai 
7 Potassium bromide (IR grade) Merck, Goa 
8 Potassium dihydrogen sulphate Central drug house (p) ltd, mumbai 
9 Sodium chloride Sisco research laboratories pvt ltd, Mumbai 
10 Potassium chloride Sisco research laboratories pvt ltd, Mumbai 
11 PVPK-30 Sisco research laboratories pvt ltd, Mumbai 
12 Lactose Otto reagents 
13 Talc Otto Chemika-Biochemika reagents 
14 Magnesium Stearate Loba chemie pvt, ltd,mumbai 
15 Hydrochloric Acid Merck specialties Pvt Ltd, Mumbai 
16 Methanol Loba chemie pvt ,ltd,Mumbai 
17 Acetone Sisco research laboratories pvt ltd, Mumbai 
18 Ethanol Loba chemie pvt ,ltd,mumbai 
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Table 2 List of Equipment Used 
S.No INSTRUMENTS SOURCE 
1 Tablet compression machine Cadmach, Ahmedabad. 
2 Mechanical sieve shaker Hicon, grover enterprises New Delhi. 
3 Hot air oven for drying Hicon, grover enterprises New Delhi. 
4 Electronic weighing balance Shimadzu, Japan. 
5 FTIR Alphar T0, Bruker, New Delhi 
6 Dissolution tester Electro lab TDT- 08L 
7 UV- spectrophotometer UV-1700, Shimadzu, Mumbai 
8 Hardness tester Monsanto 
9 Bulk density apparatus Electro lab 
10 Friabilator Electrolab, Mumbai. 
11 pH meter L I 120, Elico India Pvt ltd. 
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METHODS 
PREFORMULATION STUDIES 
Standard curve of candesartan cilexetil
83
  
The λ max of candesartan cilexetil in 0.1 N HCl was scanned to be 210 nm using UV 
spectrometer. The drug was dissolved in required quantity of 0.1N HCl and the volume 
was made 100 ml using 0.1N HCl. From this stock solution series of concentration was 
prepared. From the above solutions 2,4,6,8,10 ml was taken to dilute to 10ml using 
0.1N HCl to obtain the concentration of  2,4,6,8,10µg/ml. 
 
 Drug-excipient compatibility studies
84,85
 
 IR Spectroscopy 
IR spectra of pure candesartan cilexetil, additives and combination of candesartan 
cilexetil with additives were obtained by using Perkin-Elmer Fourier transform infrared 
spectrophotometer using KBr pellets. KBr pellets were prepared by gently mixing the 
sample with KBr. The scanning range used was 4000 to 400cm
-1
.  
The results were given in results and discussion section. 
Angle of repose
86
 
It was measured by fixed funnel technique. In this technique a funnel containing 
aceclofenac was kept at a fixed height, and it was allowed to flow to the surface which 
contains graph paper. This is due to gravitational force. The height and radius of the 
heap formed was measured. The formula for angle of repose (θ) was  
θ = tan-1(h/r) 
The results were recorded and given in results and discussion. 
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Bulk density & Tapped density
87
 
Bulk densities of granules were determined by pouring gently 20 gm of sample through 
a glass funnel into a 100 ml graduated cylinder. The volume occupied by the sample was 
recorded. Bulk density and tapped density were calculated by the formula 
 
 
 
The results were recorded and given in the results and discussion. 
 
Compressibility Index
87
 
CI of the powder was determined from the bulk and tap density as follows
4
 
 
The results were recorded and given in the results and discussion. 
 
Hausner’s ratio
87
 
It was calculated as 
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FORMULATION OF CANDESARTAN CILEXETIL FLOATING TABLETS (CF1 – CF6) 
Table 3 Formula for candesartan cilexetil floating tablets (CF1 – CF6) 
S.No Ingredients CF1 
(mg) 
CF2 
(mg) 
CF3 
(mg) 
CF4 
(mg) 
CF5 
(mg) 
CF6 
(mg) 
1 Candesartan   cilexetil 30 30 30 30 30 30 
2 HPMC 100 - - 50 50 - 
3 Carbopol 934 - 100 - 50 - 50 
4 Xanthum gum - - 100 - 50 50 
5 Tartaric acid 30 30 30 30 30 30 
6 Sodium bicarbonate 30 30 30 30 30 30 
7 Lactose 10 10 10 10 10 10 
8 Magnesium stearate 5 5 5 5 5 5 
9 Talc 5 5 5 5 5 5 
Weight of the tablet (mg) 210 210 210 210 210 210 
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Candesartan cilexetil floating tablets were prepared by direct compression method. 
Accurately weighed quantities of additives were placed in a mortar and mixed well 
gradually with constant kneading to ensure homogenous mass. The granules were 
lubricated with 1 % magnesium stearate and finally again lubricated with talc. Finally 
the lubricated granules were directly compressed into tablets on a tablet punching 
machine. 
 
EVALUATION OF CANDESARTAN CILEXETIL FLOATING TABLETS 
Weight variation 
Twenty tablets were selected at random and the average weight was determined. Not 
more than two of the individual weights deviate from the average by more than the 
percentage shown in table below and none deviates by more than twice that 
percentage.
88
  
The results were given in results and discussion section. 
Thickness  
Thickness of the tablet is measured by using Vernier caliper.  
The results were given in results and discussion section. 
Hardness  
Hardness was measured using Pfizer hardness tester which measure the pressure 
required to break the diametrical placed tablets by the pressure with coiled spring.
89,90
 
The results were given in results and discussion section. 
Friability  
Twenty tablets were weighed and placed in the friabilator. The initial weight, final 
weight and the individual weight of the tablets were determined. The friability was 
47 
 
determined as the percentage loss in the weight of the tablets. A loss of less than 0.5 to 
1% in weight is generally considered acceptable.
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The results were given in results and discussion section. 
Content uniformity  
It is the amount of drug present in each tablets. Twenty tablets were weighed and 
powdered. 0.05gm equivalent to candesartan cilexetil was weighed and transferred into 
100ml volumetric flask, dissolved and volume made upto 100ml. From this solution 5 
ml was to diluted to 50ml with 0.1N HCl. The absorbance was measured at 210nm 
using UV spectrophotometer.
92
 
The results were given in results and discussion section. 
 
Floating lag time  
The floating lag time is determined in order to assess the time taken by the dosage to 
float on the top of the dissolution medium, after placing the dosage form in the 
medium. The time required to float is noted.
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The results were given in results and discussion section. 
 
Floating time 
It is the time the tablet constantly floats on the dissolution medium (i.e duration of 
floating) in the dissolution medium.
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The results were given in results and discussion section. 
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Dissolution studies
94
 
The dissolution medium used was 0.1N HCl. 900ml of dissolution medium was used in 
each dissolution vessel and paddle type apparatus was used. The temperature 
maintained at temperature 37± 0.5
0
C and rotated at 75 rpm. The tablets of candesartan 
cilexetil were placed in dissolution medium. About 5ml of the dissolution medium was 
pipetted out for every sampling time and the volume was adjusted using by replacing 
with 5ml of 0.1N HCl. The samples collected in volumetric flask and the volume was 
made up to 10ml with 0.1N HCl.  The drug content was identified by the usual method 
given in drug content section.  
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6. RESULTS AND DISCUSSION 
 
PREFORMULATION STUDIES 
Standard Graph of Candesartan Cilexetil  
Table 4   Standard graph of Candesartan cilexetil 
   S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 2 0.072 
3 4 0.138 
4 6 0.189 
5 8 0.274 
6 10 0.365 
 
 
 
Fig 5. Standard graph of candesartan cilexetil in 0.1N HCl 
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From the graph it indicated that the concentration –absorbance curve for candesartan 
cilexetil followed the Beer Lambert’s law. 
Compatibility studies 
FTIR studies 
The FTIR graphs for the candesartan cilexetil and candesartan cilexetil with additives 
were given below. 
 
Fig 6. FTIR of candesartan cilexetil 
 
Fig 7. FTIR of candesartan cilexetil + carbopol 934 
From the above FTIR graphs it was concluded that candesartan cilexetil has no 
interaction with additives. 
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EVALUATION OF BLEND  
Table 5 Flow properties – angle of repose, bulk density and tapped density 
Formulation Angle of 
repose(θ) 
Bulk density 
(gm/cm
3
) 
Tapped density 
(gm/cm
3
) 
CF1 23.60±0.40 0.26±0.03 0.34±0.03 
CF2 22.72±0.48 0.37±0.02 0.42±0.06 
CF3 22.56±0.50 0.35±0.04 0.36±0.01 
CF4 22.64±0.50 0.28±0.02 0.33±0.03 
CF5 22.92±0.45 0.28±0.02 0.48±0.02 
CF6 23.42±0.42 0.26±0.02 0.31±0.02 
 
Table 6 Flow properties – Carr’s index and Hausner’s ratio 
Formulation  Carr’s index (%) Hausner’s ratio 
CF1 15.06±0.01 1.17±0.01 
CF2 26.06±0.01 1.37±0.02 
CF3 15.39±0.06 1.11±0.03 
CF4 15.02±0.03 1.17±0.04 
CF5 8.57±0.04 1.14±0.05 
CF6 18.39±0.01 1.24±0.02 
 
From the values of the angle of repose, bulk density, tapped density, carr’s index and 
Hausner’s ratio it was found that almost all granules for the formulation possessed good 
flow property. 
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EVALUATION OF FLOATING TABLET 
 
Weight variation:  
The total weight of each formulation is not maintained constant but the weight variation 
is in the range of ± 5% w/w indicating good control of compression process 
Table 7 Weight Variation 
S.NO. FORMULATIONS WEIGHT 
VARIATION(mg) 
1 CF1 210±0.04 
2 CF2 210±0.02 
3 CF3 210±0.02 
4 CF4 210±0.02 
5 CF5 210±0.03 
6 CF6 210±0.02 
 
From the weight variation results it was found that there is no loss in manufacturing 
process which indicated that the process followed is good. 
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Friability  
The friability was determined as the percentage loss in the weight of the tablets. A loss 
of less than 0.5 to 1% in weight is generally considered acceptable. 
Table 8 Percentage Friability 
S.NO FORMULATIONS FRIABILITY (%) 
1 CF1 0.27±0.12 
2 CF2 0.37±0.16 
3 CF3 0.52±0.14 
4 CF4 0.53±0.22 
5 CF5 0.21±0.13 
6 CF6 0.22±0.12 
 
From the results of friability, it was found that all the trials were successful and passed 
the quality control test for friability. 
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Hardness & Thickness 
Table 9 Hardness & Thickness 
S.No Formulations Hardness 
(Kgs) 
Thickness 
(mm) 
1 CF1 4.5±0.20 3.0±0.1 
2 CF2 5.2±0.12 2.9±0.5 
3 CF3 4.6±0.11 3.1±0.2 
4 CF4 5.2±0.16 3.2±0.2 
5 CF5 5.5±0.09 3.0±0.2 
6 CF6 6.8±0.04 2.9±0.1 
 
From the results of Hardness and Thickness it was found that the all formulations 
prepared were possessing suitable hardness and thickness. All of the trials comply with 
the standards. 
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Drug content 
Table 10 Percentage Drug content 
S.No Formulation Drug content (%) 
1 CF1 98.1±0.2 
2 CF2 98.1±0.1 
3 CF3 98.1 ±0.1 
4 CF4 98.1±0.5 
5 CF5 99.2±0.2 
6 CF6 98.1±0.2 
 
The formulations possessed almost nearing 100%, which indicated that there is no loss 
of drug during manufacturing or with additives. 
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Floating lag time & Floating time 
The floating lag time is determined in order to assess the time taken by the dosage to 
float on the top of the dissolution medium, after placing the dosage form in the 
medium. 
Table 11 Floating lag time & Floating time 
 
 
 
 
 
 
 
 
S.NO FORMULATION FLOATING LAG TIME  
(sec) 
FLOATING TIME (hrs) 
1 CF1 42 6 
2 CF2 120 5 
3 CF3 122 8 
4 CF4 35 7 
5 CF5 45 8 
6 CF6 122 7 
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In vitro release 
Table 12 In vitro release for CF1 – CF6 
 % DRUG RELEASE 
Formulations/ CF1 CF2 CF3 CF4 CF5 CF6 
Time (h) 
0 0 0 0 0 0 0 
0.5 12.31± 
0.11 
12.63± 
0.12 
23.33± 
0.12 
17.95± 
0.31 
12.92± 
0.13 
17.11± 
0.31 
1 16.22± 
0.12 
24.93± 
0.14 
42.53± 
0.15 
22.76± 
0.16 
23.72± 
0.31 
21.41± 
0.21 
2 24.93± 
0.13 
32.15± 
0.12 
63.15± 
0.15 
39.37± 
0.31 
36.62± 
0.31 
36.11± 
0.31 
4 38.11± 
0.21 
44.32± 
0.13 
62.83± 
0.11 
45.44± 
0.12 
46.83± 
0.66 
42.32± 
0.23 
6 45.51± 
0.31 
53.64± 
0.23 
69.43± 
0.45 
57.43± 
0.21 
67.36± 
0.12 
58.73± 
0.34 
8 53.66± 
0.21 
56.15± 
0.35 
71.23± 
0.24 
73.36± 
0.26 
80.39± 
0.12 
71.45± 
0.24 
16 66.42± 
0.21 
62.16± 
0.21 
84.35± 
0.33 
91.53± 
0.33 
93.13± 
0.21 
87.97± 
0.12 
24 69.22± 
0.36 
66.33± 
0.12 
89.63± 
0.41 
92.33± 
0.21 
99.12± 
0.43 
93.19± 
0.55 
 
 
 
 
 
 
 
 
 
58 
 
 
 
 
Fig 8 In vitro release for CF1 – CF6 
 
From the in vitro release studies the trials CF1, CF2, CF3, CF4, CF5 and CF6 percent 
release was found to be 69.22±0.36, 66.33±0.12, 89.63±0.41, 92.33±0.21, 99.12±0.43, 
and 93.19±0.55 respectively. From the in vitro release results it was found that the trial 
CF5 was best amongst the trials. 
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7. SUMMARY AND CONCLUSION 
 
Oral delivery of drugs is one of the most preferable routes of delivery due to the ease of 
administration, patient compliance and flexibility in formulation etc.  
Floating systems significantly extend the period of time, over which drug may 
be released and prolongs dosing intervals and increase patient compliance. These 
systems retain in stomach and improve the absorption window and thus enhance the 
bioavailability. 
Floating dosage forms are oral dosage forms of tablets, capsules, or micro beads 
and contain hydrocolloids that allow floating by swelling thereby prolong the residence 
time of dosage form within G.I tract. 
             Floating drug delivery or gastroretentive systems gastric emptying is an 
extremely variable process and ability to prolong and control the emptying time is a 
valuable asset for dosage forms, which reside in the stomach for a longer period of time 
than conventional dosage forms.  
             Floating drug delivery system (FDDS) could prolong GRT to obtain sufficient 
drug bioavailability . The system basically floats in the gastric fluid because of its 
lower density compared to that of the aqueous medium. FDDS is desirable for drugs 
with an absorption window in the stomach or in the upper small intestine. 
Certain factors like density, size, shape, fast or fed conditions, nature of meal, 
age, posture, other drugs, biological factors may affect the gastric retention.  
Candesartan cilexetil is a drug used in the treatment of hypertension. In the 
present project floating tablets were designed and executed. 
            Floating tablets of candesartan cilexetil were developed to prolong gastric 
residence time and to increase its bioavailability.  
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Six formulations (CF1 to CF6) of floating tablets of candesartan cilexetil were 
prepared by using individual and combination of polymers. HPMC, carbopol 934 and 
xanthum gum were used as polymer to retard the release of the drug in controlled 
manner.  
Flow properties of the prepared granules for CF1 – CF6 were determined and it 
was found that the results were within the standard limits and specifications. 
 The floating tablets were prepared by direct compression method. Direct 
compression method is a suitable method for drugs which are sensitive to heat and 
moisture. Probably it saves the time also. In the present project the formulations were 
easily and quickly prepared because of the employment of direct compression.  
The compressed tablets (CF1 – CF6) were evaluated for various tests quality 
control tests weight variation, content uniformity, friability, hardness, floating time, 
floating lag time and in vitro release studies. 
  The hardness and friability of the tablets (CF1 – CF6)  were within the limits.  
The weight variations of the tablets (CF1 – CF6) were found to be within the 
limits.  
The content uniformity of the prepared tablets (CF1 – CF6) were within the 
limits.  
The floating time and floating lag time for the prepared formulations (CF1 – 
CF6) was good. 
 From the in vitro release studies the trials CF1, CF2, CF3, CF4, CF5 and CF6 
percent release at the end of the 24
th
 hour  was found to be 69.22±0.36, 66.33±0.12, 
89.63±0.41, 92.33±0.21, 99.12±0.43, and 93.19±0.55 respectively. From the in vitro 
release results it was found that the trial CF5 was best amongst the trials. 
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 The formulation (CF5) with hydroxypropylmethyl cellulose and xanthum gum 
was found  to be best formulation with  floating time of  8 hrs and  in vitro drug release 
of about 99.12±0.43% at the end of 24
th
 hour. 
 
CONCLUSION 
The present work was based on the floating drug delivery of candesartan cilexetil. 
Floating tablets of candesartan cilexetil were formulated and evaluated. Based on the in 
vitro evaluation studies, optimized trial was found to be CF5 with good in vitro 
properties.  
Hence it is ideal to formulate floating tablets for candesartan cilexetil.  
However in future it is needed to carryout in vivo studies to implement candesartan 
cilexetil as commercial product.  
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